Lantheus Holdings, Inc. (LNTH)
| Market Cap | 4.31B |
| Revenue (ttm) | 541.58M |
| Net Income (ttm) | -37.33M |
| Shares Out | 68.63M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | 31.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,139,749 |
| Open | 62.33 |
| Previous Close | 61.29 |
| Day's Range | 61.01 - 64.32 |
| 52-Week Range | 22.20 - 73.78 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 93.64 (+49.1%) |
| Earnings Date | Jul 27, 2022 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-label... [Read more...]
Financial Performance
In 2021, LNTH's revenue was $425.21 million, an increase of 25.28% compared to the previous year's $339.41 million. Losses were -$71.28 million, 429.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for LNTH stock is "Buy." The 12-month stock price forecast is 93.64, which is an increase of 49.06% from the latest price.
News
Best Growth Stocks to Buy for June 24th
MPC, LNTH, and LUV made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24, 2022.
Best Growth Stocks to Buy for June 20th
MPC, CLR, and LNTH made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 20, 2022.
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations
Lantheus Holdings (LNTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Lantheus Holdings (LNTH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imagi...
Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Me...
Lantheus' PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessm...
Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNM...
How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 27%
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, th...
What Makes Lantheus Holdings (LNTH) a Good Fit for "Trend Investing"
Lantheus Holdings (LNTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it thro...
Lantheus to Present at the Jefferies Healthcare Conference
NORTH BILLERICA, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diag...
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at t...
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagn...
Wall Street Analysts Predict a 44% Upside in Lantheus Holdings (LNTH): Here's What You Should Know
The consensus price target hints at a 44.2% upside potential for Lantheus Holdings (LNTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...
Lantheus Hosts Inaugural Investor Day
Lantheus Outlines Sustainable and Profitable Growth Strategy; Introduces Long-Term Financial Targets Lantheus Outlines Sustainable and Profitable Growth Strategy; Introduces Long-Term Financial Targets
Lantheus Holdings (LNTH) Just Overtook the 20-Day Moving Average
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Lantheus Holdings (LNTH) Is a Great Choice for "Trend" Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Lantheus Holdings (LNTH) could be a great choice. It is one of the several stocks that passed through our "Recent...
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
Retrospective analysis demonstrates reliability of PSMA scan indices as response-imaging biomarker to androgen therapy in prostate cancer Retrospective analysis demonstrates reliability of PSMA scan ind...
New Analysts Initiate Coverage: Top 5 Stocks on Radar
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Bancolombia (CIB), Lantheus (LNTH), A-Mark (AMRK), Patrick (PATK) and LCI (LCII).
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Ce...
NM-01 is a novel technetium-99m SPECT imaging agent currently being developed for the assessment of PD-L1 expression in cancer cells NM-01 is a novel technetium-99m SPECT imaging agent currently being d...
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
PYLARIFY® (piflufolastat F18) injection was the first commercially available PSMA-targeted PET imaging agent for prostate cancer PYLARIFY® (piflufolastat F18) injection was the first commercially availa...
Lantheus to Present at the UBS Global Healthcare Conference
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagn...
Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?
Here is how Lantheus Holdings (LNTH) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for May 6th
LNTH, TGLS, and APA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2022.
Why Lantheus Holdings' Shares Are Up 16.4% Friday
A better-than-expected earnings report has investors buying.
Lantheus Holdings (LNTH) Beats Q1 Earnings and Revenue Estimates
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 110.87% and 26.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
NORTH BILLERICA, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnost...